Breast Surgeons Live
Back to Activities List
Session Title:
Post-neoadjuvant Axillary Management in the cN+ Patient With and Without Nodal pCR
Date & Time:
February 12, 2025, 7:00 PM–8:00 PM ET
Length:
1 Hour
CME Deadline:
February 12, 2026
Log in to access members-only content.
Target Audience:
Surgeons with a special interest in the treatment of breast disease.
Objectives:
At the end of this activity, participants will be able to:
- Define trial design including enrolled population of NSABP B51 and recently published outcomes along with implementation.
- Discuss implications of trial data on current adjuvant radiation therapy recommendations with case examples.
- Review real world data regarding axillary management after chemotherapy for node positive patients.
Description:
This webinar will highlight findings from recently resulted NSABP B-51 trial including implications for adjuvant radiation fields and immediate reconstruction. The discussion will also review current practice patterns in node positive patients after neoadjuvant chemotherapy while awaiting results from A11202. The hour will close with a case discussion regarding post-neoadjuvant axillary management.
Agenda:
Welcome and Introduction
Terry Mamounas, MD, MPH
NSABP B51 Results & Practice Implications
Julia White, MD
Who Still Needs an Axillary Dissection After Neoadjuvant Chemotherapy and Is This Happening? Real World Updates as We Await A11202 Data?
Judy C. Boughey, MD
Axillary Management Case Discussion: Who to Dissect, Who to Radiate, Who Needs Both?
Bruce Haffty, MD, and Giacomo Montagna, MD, MPH
Q&A
Faculty:
Moderator—Terry Mamounas, MD, MPH
Advent Health Cancer Institute
Orlando, FL
Judy C. Boughey, MD, FACS
Mayo Clinic
Rochester, MN
Bruce Haffty, MD
Cancer Institute of New Jersey
New Brunswick, NJ
Giacomo Montagna, MD, MPH
Memorial Sloan Kettering Cancer Center
New York, NY
Julia White, MD
University of Kansas Cancer Center
Kansas City, KS
References:
- Boughey, J.C., et al., Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial. Ann Surg Oncol, 2023. 30(11): p. 6401-6410.
- Weiss, A., et al., Contemporary Axillary Surgical Management in Patients with Pathologically Node Positive Disease After Neoadjuvant Chemotherapy: A Survey of Members of the American Society of Breast Surgeons. Ann Surg Oncol, 2024.
- Weiss, A., et al., ASO Author Reflections: Extreme Early Adoption-The Omission of Axillary Lymph Node Dissection is Being Adopted into Practice Before Clinical Trial Data are Available: Where Might this Lead? Ann Surg Oncol, 2024.
- Wong, S.M., et al., Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. Ann Surg Oncol, 2019. 26(11): p. 3517-3525.
- Moore, A.M., et al., Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol, 2024.
Disclosures:
coming soon
